



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 21 Nov 2016 (#40)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- NIH Request for Information (RFI) on Strategies for NIH Data Management, Sharing, and Citation ([NOT-OD-17-015](#))
- Publication of the Revised NIH Grants Policy Statement (Rev. November 2016) for FY 2017 ([NOT-OD-17-021](#))
- Request for Information (RFI): Draft Strategic Plan for the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health ([NOT-AA-16-010](#))
- Request for Proposals (RFP): NIAID/Division of AIDS: Reagent Resource Support Program for AIDS Vaccine Development, NIAID-DAIDS-NIHAI2016069 ([NOT-AI-17-007](#))
- Notice of Change to Budget Instructions for PA-16-252 "Gene Fusions in Pediatric Sarcoma (R21)" ([NOT-CA-17-002](#))
- Notice of Correction to RFA-CA-16-016 "Population-based Research to Optimize the Screening Process (PROSPR) (UM1)" to Clarify the Expectations Regarding the Minimal Sizes of Screening-eligible Patient Populations in Participating Healthcare Systems ([NOT-CA-17-004](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Neuroscience Research on Drug Abuse (R01) ([NOT-DA-17-001](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Zika Virus (ZIKV) Complications (R21) ([NOT-HD-16-033](#))

1. Enhancing the Target and Biomarker Discovery Efforts of the AMP-AD and M2OVE-AD Consortia

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [RFA-AG-17-054](#)

Type: R01

Application Due Date: February 3, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This funding opportunity invites applications that would enhance the goals and deliverables of the AMP-AD Target Discovery and Preclinical Validation and M2OVE Consortia by maximizing the usability of the data and analytical results generated by these programs, seizing opportunities for additional target and biomarker discovery, and accelerating the validation of the novel targets and biomarkers being discovered within the AMP-AD and M2OVE-AD Consortia.

Budget: NIA intends to commit \$5 million in FY 2017 to fund 3-5 awards. The number of awards is contingent upon NIH appropriations. Annual direct costs are capped at \$750,000. The total project period for an application submitted in response to this FOA may not exceed 3 years.

2. Systems Biology: The Next Generation for Infectious Diseases

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [RFA-AI-16-080](#)

Type: U19

Application Due Date: March 15, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) solicits applications to establish Systems Biology Centers that use systems biology approaches to build predictive models for infectious diseases. These models will be derived from hypotheses related to systems-level host/pathogen molecular interactions during infection or treatment using integrated datasets generated from a combination of high-throughput experimental approaches, including omics technologies and computational approaches. Importantly, the Centers must clearly integrate experimental approaches and computational modeling to test and validate hypotheses of significance to the infectious diseases field.

Budget: NIAID intends to commit \$11 million in FY2018 to fund up to 5 awards. Budgets for direct costs of up to \$2,000,000 per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antimicrobial-Resistant Gram-Negative Bacteria

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-16-081\)](#)

Type: R01

Application Due Date: May 17, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support milestone-driven projects focused on developing and utilizing novel predictive assays, models and/or research tools based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Enterobacteriaceae (CRE), MDR Acinetobacter and/or MDR Pseudomonas aeruginosa.

Budget: NIAID intends to commit \$9.0 million in FY 2018 to fund 10-15 awards. Budgets for direct costs of up to \$750,000 per year may be requested. Applicants may also request up to an additional \$300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling \$1,050,000 direct costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Leveraging Existing Cohort Studies to Clarify Risk and Protective Factors for Alzheimers Disease and Related Dementias

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-054\)](#)

Type: R01

Application Due Date: [Standard dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This FOA invites applications that will combine multiple cohorts in order to improve statistical power and clarify risk and protective factors for Alzheimer's disease and related dementias (AD/ADRD).

Budget: NIA intends to fund an estimate of 5-8 awards, corresponding to a total of \$8 million for fiscal year 2017. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

5. Global Infectious Disease Research Training Program

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-057\)](#)

Type: D43

Application Due Date: July 27, 2017; July 26, 2018; July 25, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages applications for the Global Infectious Disease (GID) Research Training Program from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of an LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs.

Budget: Applications budgets are limited to \$230,000 per year for new awards and \$276,000 per year for renewal awards (total direct costs). The maximum project period is up to 5 years.

6. Planning Grant for Global Infectious Disease Research Training Program

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-058\)](#)

Type: D71

Application Due Date: July, 27, 2017; July 26, 2018; July 25, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages applications for a planning grant from institutions in low- and middle-income countries (LMICs) to design a Global Infectious Disease (GID) Research Training Program in collaboration with U.S. institutions. The application should propose a collaborative process to design a training program that will strengthen the capacity of the LMIC institution to conduct infectious disease research. Planning grants should describe a detailed vision for a research-training program that focuses on a major endemic or life-threatening emerging infectious disease, neglected tropical disease, infections that frequently occur as a co-infection in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs.

Budget: Applications budgets are limited to \$46,000 (total direct costs). The maximum project period is 1 year.

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements (*click on “PA” to search for further funding opportunities*)

RFA Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)

